Oncology and X-Ray products company
Varian Medical Systems
) recently revealed that it has received FDA 510(k) clearance for
its Edge radiosurgery offering. This is Varian's latest system
for carrying out radiosurgery using modern and timely movement
management and tumor monitoring know-how.
The Edge radiosurgery suite includes several technologies
which are approved by the FDA. These components may also be
rendered available as upgrades for suitable Varian systems and
may be listed as - the Calypso system, the Advanced Motion &
Image-Guided Radiotherapy package, the PerfectPitch couch and the
Intra-cranial radiosurgery package. The Beacon transponders
anchored to Calypso for lung radiosurgery are awaiting FDA 510(k)
Varian is a leading manufacturer of integrated radiotherapy
systems for cancer treatment, and a premier supplier of X-ray
tubes for diagnostic imaging applications. The company operates
in a technology-driven environment where success depends on the
use of new technology, product development and upgrades. In the
radiation oncology market, Varian competes with
The company is poised to increase its market share in
radiation oncology. It currently enjoys a healthy demand for its
coveted TrueBeam technology, which has meaningfully contributed
to its net order oncology growth. Varian's TrueBeam is designed
to treat tumors with beams of high speed and precision. It
incorporates several technological innovations such as patient
positioning and managing his/her motion. Given its high intensity
nature, TrueBeam can dispense strong dosage over twice as fast as
that possible with earlier equipment.
Moreover, Varian continues to post decent results despite the
contagion of economic problems in Europe and sustained softness
in certain end markets. It enjoys a strong balance sheet marked
by low debt and sizeable cash. The company also periodically
deploys capital to boost investor confidence via share
However, Varian competes with larger players in a
technology-intensive industry. Further, uncertainties stemming
from health care reform and a still weak hospital capital
spending environment across many developed countries, especially
in Europe, are significant challenges.
The stock carries a Zacks Rank #3, which translates into a
short-term Hold rating.
Cantel Medical Corp.
) are Zacks Rank #1 (Strong Buy) stocks which are expected to do
ACCURAY INC (ARAY): Free Stock Analysis
CANTEL MED CORP (CMN): Free Stock Analysis
CYBERONICS INC (CYBX): Free Stock Analysis
VARIAN MEDICAL (VAR): Free Stock Analysis
To read this article on Zacks.com click here.